Anavex Life Sciences Corp (AVXL)

[Investor2014]

-the 19 left all fit our profile and all have Some type of benefit regardless which dosage they’re on. It’d be nice if they provide some RWE for them

I would expect about 20% having the gene variants leading to reduced response to A2-73. I would also expect some of the remaining 80% to have issues with A2-73 blood concentration.

Unlikely we have more than 5 - 6 strong responders, but perhaps assuming dosing has been optimised some time ago.

Overall I would hope we see reduced decline compared to SOC for the remaining group.